Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cellectar Biosciences Q2 EPS $(3.39) Beats $(3.98) Estimate

Author: Benzinga Newsdesk | August 14, 2025 07:22am
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(3.39) per share which beat the analyst consensus estimate of $(3.98) by 14.72 percent. This is a 37.22 percent increase over losses of $(5.40) per share from the same period last year.

Posted In: CLRB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist